.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,863,288

« Back to Dashboard

Claims for Patent: 7,863,288

Title:Compounds and methods for kinase modulation, and indications therefor
Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
Inventor(s): Ibrahim; Prabha N. (Mountain View, CA), Artis; Dean R. (Kensington, CA), Bremer; Ryan (Oakland, CA), Mamo; Shumeye (Oakland, CA), Zhang; Chao (Moraga, CA), Zhang; Jiazhong (Foster City, CA), Tsai; James (Vallejo, CA), Hirth; Klaus-Peter (San Francisco, CA), Bollag; Gideon (Orinda, CA), Spevak; Wayne (Berkeley, CA), Cho; Hanna (Oakland, CA), Gillette; Samuel J. (Oakland, CA), Shi; Shenghua (San Diego, CA)
Assignee: Plexxikon, Inc. (Berkeley, CA)
Application Number:11/473,347
Patent Claims: 1. A compound having the structure of Formula IIIm: ##STR03440## or a pharmaceutically acceptable salt thereof, wherein: R.sup.81 is selected from the group consisting of hydrogen, halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, --OH, --NH.sub.2, --CN, --NO.sub.2, --C(O)OH, --S(O).sub.2NH.sub.2, --C(O)NH.sub.2, --C(S)NH.sub.2, --NHC(O)NH.sub.2, --NHC(S)NH.sub.2, --NHS(O).sub.2NH.sub.2, --OR.sup.68, --SR.sup.68, --NR.sup.69R.sup.68, --C(O)R.sup.68, --C(S)R.sup.68, --C(O)OR.sup.68, --C(O)NR.sup.69R.sup.68, --C(S)NR.sup.69R.sup.68, --S(O).sub.2NR.sup.69R.sup.68, --NR.sup.69C(O)R.sup.68, --NR.sup.69C(S)R.sup.68, --NR.sup.69S(O).sub.2R.sup.68, --NR.sup.69C(O)NH.sub.2, --NR.sup.69C(O)NR.sup.69R.sup.68, --NR.sup.69C(S)NH.sub.2, --NR.sup.69C(S)NR.sup.69R.sup.68, --NR.sup.69S(O).sub.2NH.sub.2, --NR.sup.69S(O).sub.2NR.sup.69R.sup.68, --S(O)R.sup.68, and --S(O).sub.2R.sup.68; R.sup.83 is selected from the group consisting of hydrogen, fluoro and chloro; R.sup.112 is selected from the group consisting of optionally substituted C.sub.2-6 alkyl, optionally substituted aryl, optionally substituted heteroaryl, and --NR.sup.79R.sup.80; R.sup.68 is selected from the group consisting of optionally substituted lower alkyl, optionally substituted lower alkenyl, provided, however, that when R.sup.68 is optionally substituted lower alkenyl, no alkene carbon thereof is bound to N, S, O, S(O), S(O).sub.2, C(O) or C(S) of --OR.sup.68, --SR.sup.68, --NR.sup.69R.sup.68, --C(O)R.sup.68, --C(S)R.sup.68, --C(O)OR.sup.68, --C(O)NR.sup.69R.sup.68, --C(S)NR.sup.69R.sup.68, --S(O).sub.2NR.sup.69R.sup.68, --NR.sup.69C(O)R.sup.68, --NR.sup.69C(S)R.sup.68, --NR.sup.69S(O).sub.2R.sub.68, --NR.sup.69C(O)NH.sub.2, --NR.sup.69C(O)NR.sup.69R.sup.68, --NR.sup.69C(S)NH.sub.2, --NR.sup.69C(S)NR.sup.69R.sup.68, --NR.sup.69S(O).sub.2NH.sub.2, --NR.sup.69S(O).sub.2NR.sup.69R.sup.68, --S(O)R.sup.68, or --S(O).sub.2R.sup.68, optionally substituted lower alkynyl, provided, however, that when R.sup.68 is optionally substituted lower alkynyl, no alkyne carbon thereof is bound to N, S, O, S(O), S(O).sub.2, C(O) or C(S) of --OR.sup.68, --SR.sup.68, --NR.sup.69R.sup.68, --C(O)R.sup.68, --C(S)R.sup.68, --C(O)OR.sup.68, --C(O)NR.sup.69R.sup.68, --C(S)NR.sup.69R.sup.68, --S(O).sub.2NR.sup.69R.sup.68, --NR.sup.69C(O)R.sup.68, --NR.sup.69C(S)R.sup.68, --NR.sup.69S(O).sub.2R.sup.68, --NR.sup.69C(O)NH.sub.2, --NR.sup.69C(O)NR.sup.69R.sup.68, --NR.sup.69C(S)NH.sub.2, --NR.sup.69C(S)NR.sup.69R.sup.68, --NR.sup.69S(O).sub.2NH.sub.2, --NR.sup.69S(O).sub.2NR.sup.69R.sup.68, --S(O)R.sup.68, or --S(O).sub.2R.sup.68, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; R.sup.69 is selected from the group consisting of hydrogen and optionally substituted lower alkyl; and R.sup.79 and R.sup.80 are independently hydrogen or optionally substituted lower alkyl, or R.sup.79 and R.sup.80 combine with the nitrogen to which they are attached to form optionally substituted 5-7 membered heterocycloalkyl.

2. A composition comprising: a pharmaceutically acceptable carrier; and a compound according to claim 1.

3. A kit comprising a compound according to claim 1.

4. The compound of claim 1, wherein: R.sup.81 is selected from the group consisting of hydrogen, halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, --CN, --S(O).sub.2NH.sub.2, --C(O)NH.sub.2, --OR.sup.68, --SR.sup.68, --NR.sup.69R.sup.68, --C(O)R.sup.68, --C(S)R.sup.68, --C(O)NR.sup.69R.sup.68, --S(O).sub.2NR.sup.69R.sup.68, --NR.sup.69C(O)R.sup.68, --NR.sup.69S(O).sub.2R.sup.68, --S(O)R.sup.68, and --S(O).sub.2R.sup.68.

5. The compound of claim 4, wherein: lower alkyl as R.sup.68, R.sup.69, R.sup.79, R.sup.80, or R.sup.81, C.sub.2-6 alkyl as R.sup.112, lower alkenyl as R.sup.68 or R.sup.81, or lower alkynyl as R.sup.68 or R.sup.81 are optionally substituted with 1, 2, or 3 substituents selected from the group consisting of fluoro, --NO.sub.2, --CN, --NR.sup.1aR.sup.1a, --OC(O)R.sup.1a, --OC(S)R.sup.1a, --C(O)R.sup.1a, --C(S)R.sup.1a, --C(O)OR.sup.1a, --C(S)OR.sup.1a, --C(O)NR.sup.1aR.sup.1a, --C(S)NR.sup.1aR.sup.1a, --S(O).sub.2NR.sup.1aR.sup.1a, --C(NH)NR.sup.1aR.sup.1a, --NR.sup.13C(O)R.sup.1a, --NR.sup.1aC(S)R.sup.1a, --NR.sup.1aS(O).sub.2R.sup.1a, --NR.sup.1aC(O)NR.sup.1aR.sup.1a, --NR.sup.1aC(S)NR.sup.1aR.sup.1a, --NR.sup.1aS(O).sub.2NR.sup.1aR.sup.1a, --S(O)R.sup.1a, --S(O).sub.2R.sup.1a, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; cycloalkyl, heterocycloalkyl, aryl or heteroayl, as R.sup.68, R.sup.81, R.sup.112, or a substituent of lower alkyl, lower alkenyl or lower alkynyl are optionally substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, --NO.sub.2, --CN, --SR.sup.1a, --NR.sup.1aR.sup.1a, --OC(O)R.sup.1a, --OC(S)R.sup.1a, --C(O)R.sup.1a, --C(S)R.sup.1a, --C(O)OR.sup.1a, --C(S)OR.sup.1a, --C(O)NR --C(S)NR.sup.1aR.sup.1a, --S(O).sub.2NR.sup.1aR.sup.1a, --C(NH)NR.sup.1aR.sup.1a, --NR.sup.1aC(O)R.sup.1a, --NR.sup.1aC(S)R.sup.1a, --NR.sup.1aS(O).sub.2R.sup.1a, --NR.sup.1aC(O)NR.sup.1aR.sup.1a, --NR.sup.1aC(S)NR.sup.1aR.sup.1a, --NR.sup.1aS(O).sub.2NR.sup.1aR.sup.1a, --S(O)R.sup.1a, --S(O).sub.2R.sup.1a, --R.sup.1b and lower alkyl, wherein lower alkyl is optionally substituted with 1, 2 or 3 substituents selected from the group consisting of fluoro, --OH, --NH.sub.2, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, and --R.sup.1b; R.sup.1a is selected from the group consisting of hydrogen, --R.sup.1b, and lower alkyl, provided, however, that hydrogen is not bound to any of C(S), C(O), S(O), or S(O).sub.2 of --OC(O)R.sup.1a, --OC(S)R.sup.1a, --C(O)R.sup.1a, --C(S)R.sup.1a, --NR.sup.1aC(O)R.sup.1a, --NR.sup.1aC(S)R.sup.1a, --NR.sup.1aS(O).sub.2R.sup.1a, --S(O)R.sup.1a, or --S(O).sub.2R.sup.1a, wherein lower alkyl is optionally substituted with 1, 2 or 3 substituents selected from the group consisting of fluoro, --OH, --NH.sub.2, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, and --R.sup.1b, provided, however, that any substitution of the alkyl carbon bound to O, S, or N of --OR.sup.1a, --SR.sup.1a, --NR.sup.1aR.sup.1a, --C(O)OR.sup.1a, --C(S)OR.sup.1a, --C(O)NR.sup.1aR.sup.1a, --C(S)NR.sup.1aR.sup.1a, --S(O).sub.2NR.sup.1aR.sup.1a, --C(NH)NR.sup.1aR.sup.1a, --NR.sup.1aC(O)R.sup.1a, --NR.sup.1aC(S)R.sup.1a, --NR.sup.1aS(O).sub.2R.sup.1a, --NR.sup.1aC(O)NR.sup.1aR.sup.1a, --NR.sup.1aC(S)NR.sup.1aR.sup.1a, or --NR.sup.1aS(O).sub.2NR.sup.1aR.sup.1a, is fluoro or --R.sup.1b; and R.sup.1b is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with 1, 2 or 3 substituents selected from the group consisting of halogen, --CN, --OH, --NH.sub.2, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, and cycloalkylamino.

6. The compound of claim 5, wherein: lower alkyl as R.sup.68, R.sup.69, R.sup.79, R.sup.80, or R.sup.8, C.sub.2-6 alkyl as R.sup.112, lower alkenyl as R.sup.68 or R.sup.81, or lower alkynyl as R.sup.68 or R.sup.81 are optionally substituted with 1, 2, or 3 substituents selected from the group consisting of fluoro, --CN, --SR.sup.1a, --NR.sup.1aR.sup.1a, --C(O)R.sup.1a, --C(S)R.sup.1a, --C(O)OR.sup.1a, --C(O)NR.sup.1aR.sup.1a, --C(S)NR.sup.1aR.sup.1a, --S(O).sub.2NR.sup.1aR.sup.1a, --NR.sup.1aC(O)R.sup.1a, --NR.sup.1aC(S)R.sup.1a, --NR.sup.1aS(O).sub.2R.sup.1a, --S(O)R.sup.1a, --S(O).sub.2R.sup.1a, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; and cycloalkyl, heterocycloalkyl, aryl or heteroayl, as R.sup.68, R.sup.81, R.sup.112, or a substituent of lower alkyl, lower alkenyl or lower alkynyl are optionally substituted with 1, 2, or 3 substituents selected from the group consisting of halogen, --CN, --NR.sup.1aR.sup.1a, --SR.sup.1aR.sup.1a, --C(O)R.sup.1a, --C(S)R.sup.1a, --C(O)NR.sup.1aR.sup.1a, --C(S)NR.sup.1aR.sup.1a, --S(O).sub.2NR.sup.1aR.sup.1a, --NR.sup.1aC(O)R.sup.1a, --NR.sup.1aC(S)R.sup.1a, --NR.sup.1aS(O).sub.2R.sup.1a, --S(O)R.sup.1a, --S(O).sub.2R.sup.1a, --R.sup.1b, and lower alkyl, wherein lower alkyl is optionally substituted with 1, 2 or 3 substituents selected from the group consisting of fluoro, --OH, --NH.sub.2, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, and --R.sup.ib.

7. The compound of claim 6, wherein R.sup.112 is optionally substituted C.sub.2-6 alkyl.

8. The compound of claim 6, wherein R.sup.112 is --NR.sup.79R.sup.80.

9. The compound of claim 6, wherein R.sup.112 is optionally substituted aryl.

10. The compound of claim 6, wherein R.sup.112 is optionally substituted heteroaryl.

11. The compound of claim 1, wherein: R.sup.81 is selected from the group consisting of hydrogen; halogen; C.sub.1-6 alkyl optionally substituted with carboxylic acid; C.sub.2-6 alkenyl optionally substituted with carboxylic acid; C.sub.1-6 alkoxy optionally substituted with methoxy or diethylamine; carboxylic acid; carboxylic acid methyl ester; carboxylic acid ethylamide; 4-methyl-piperidin-1-yl; 4-methyl-piperazin-1-yl; morpholin-4-yl; phenyl-amino; phenyl optionally substituted with halogen, --CN, optionally fluoro substituted C.sub.1-6 alkyl, dimethylamine, methoxy, carboxylic acid, carboxylic acid amide, carboxylic acid-dimethyl amide, morpholine-4-carbonyl, morpholine, morpholine-4-methyl, or 2-methoxy-ethoxy; midinyl optionally substituted with methoxy, morpholine, or 4-methyl-piperazin-1-yl; 4-meth 1-1H-imidazol-2-yl; and N-methyl-pyrazolyl; R.sup.83 is selected from the group consisting of hydrogen, fluoro and chloro; R.sup.112 is selected from the group consisting of C.sub.2-6 alkyl; phenyl optionally substituted with --CN, --NO.sub.2, acetamide, halogen, optionally fluoro substituted C.sub.1-6alkyl, optionally fluoro substituted C.sub.1-6 alkoxy, or oxazolyl; 2,3-dihydro-benzo[1,4]dioxin-6-yl; methyl substituted thiazole, methyl substituted imidazole, thiophene optionally substituted with methyl, oxazole, isoxazole, or pyridine; furan substituted with methyl or carboxylic acid methyl ester; benzothiazol-6-yl; benzo[b]thiophen-2-yl; piperidin-1-yl; and dimethylamine.

12. The compound of claim 11, wherein R.sup.112 is C.sub.2-6 alkyl.

13. The compound of claim 11, wherein R.sup.112 is piperidin-1-yl or dimethylamine.

14. The compound of claim 11, wherein R.sup.112 is selected from the group consisting of 2,3-dihydro-benzo[1,4]dioxin-6-yl; and phenyl optionally substituted with --CN, acetamide, halogen, optionally fluoro substituted C.sub.1-6 alkyl, optionally fluoro substituted C.sub.1-6 alkoxy, or oxazolyl.

15. The compound of claim 11, wherein R.sup.112 is selected from the group consisting of methyl substituted thiazole; methyl substituted imidazole; thiophene optionally substituted with methyl, oxazole, isoxazole, or pyridine; furan substituted with methyl or carboxylic acid methyl ester; benzothiazol-6-yl; and benzo[b]thiophen-2-yl.

16. The compound of claim 1, wherein the compound is selected from the group consisting of: Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-a- mide, Propane-1-sulfonic acid [3-(5-ethoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, Propane-1-sulfonic acid [2-fluoro-3-(5-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amid- e, Propane-1-sulfonic acid {3-[5-(2-diethylamino-ethoxy)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-d- ifluoro-phenyl}-amide, Butane-1-sulfonic acid [2,4-difluoro-3-(5-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-- amide, and pharmaceutically acceptable salts thereof.

17. The compound of claim 1, wherein the compound is selected from the group consisting of: Propane-1-sulfonic acid [2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide, Propane-1-sulfonic acid [2,4-difluoro-3-(5-isopropenyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phen- yl]-amide, Propane-1-sulfonic acid [2,4-difluoro-3-(5-isopropyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl- ]-amide, Propane-1-sulfonic acid [2,4-difluoro-3-(5-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-a- mide, Propane-1-sulfonic acid [4-chloro-2-fluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide- , Propane-1-sulfonic acid [2-fluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide, 3-3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]p- yridin-5-yl-acrylic acid, 3-3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]p- yridin-5-yl-propionic acid, Butane-1-sulfonic acid [3-(chloro-1H-pyrrolo[2 b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, Propane-1-sulfonic acid [2,4-difluoro-3-(5-fluoro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phen- yl]-amide, Propane-1-sulfonic acid [4-chloro-3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phen- yl]-amide, and pharmaceutically acceptable salts thereof.

18. The compound of claim 1, wherein the compound is selected from the group consisting of: 3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyr- idine-5-carboxylic acid methyl ester, 3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyr- idine-5-carboxylic acid, 3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyr- idine-5-carboxylic acid ethylamide, and pharmaceutically acceptable salts thereof.

19. The compound of claim 1, wherein the compound is selected from the group consisting of: Propane-1-sulfonic acid [4-chloro-2-fluoro-3-(5-phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phen- yl]-amide, Propane-1-sulfonic acid [2,4-difluoro-3-(5-phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-a- mide, Propane-1-sulfonic acid {3-[5-(4-dimethylamino-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-- difluoro-phenyl}-amide, Propane-1-sulfonic acid {2,4-difluoro-3-[5-(4-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbony- l]-phenyl}-amide, Propane-1-sulfonic acid {2,4-difluoro-3-[5-(3-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbony- l]-phenyl}-amide, Propane-1-sulfonic acid {3-[5-(3-dimethylamino-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-- difluoro-phenyl}-amide, Propane-1-sulfonic acid [2-fluoro-3-(5-phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide- , Propane-1-sulfonic acid {2,4-difluoro-3-[5-(3-fluoro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl- ]-phenyl}-amide, Propane-1-sulfonic acid {2,4-difluoro-3-[5-(4-fluoro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl- ]-phenyl}-amide, Propane-1-sulfonic acid {3-[5-(3-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluor- o-phenyl}-amide, 3-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]- pyridin-5-yl}-benzoic acid, 4-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]- pyridin-5-yl}-benzamide, 4-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]- pyridin-5-yl}-N,N-dimethyl-benzamide, Propane-1-sulfonic acid (2,4-difluoro-3-{5-[4-(morpholine-4-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]py- ri dine-3-carbonyl}-phenyl)-amide, Propane-1-sulfonic acid {2,4-difluoro-3-[5-(3-morpholin-4-yl-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-- carbonyl]-phenyl}-amide, Propane-1-sulfonic acid {2,4-difluoro-3-[5-(3-morpholin-4-ylmethyl-phenyl)-1H-pyrrolo[2,3-b]pyrid- ine-3-carbonyl]-phenyl}-amide, Propane-1-sulfonic acid {3-[5-(4-cyano-3,5-dimethyl-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]- -2,4-difluoro-phenyl}-amide, 3-{3-[2,6-difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]- pyridin-5-yl}-benzamide, Propane-1-sulfonic acid (2,4-difluoro-3-{5-[4-(2-methoxy-ethoxy)-phenyl]-1H-pyrrolo[2,3-b]pyridin- e-3-carbonyl}-phenyl)-amide, 4-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]- pyridin-5-yl}2,N,N-trimethyl-benzamide, and pharmaceutically acceptable salts thereof.

20. The compound of claim 1, wherein the compound is selected from the group consisting of: Propane-2-sulfonic acid [2,4-difluoro-3-(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phe- nyl]-amide, Propane-1-sulfonic acid [2-fluoro-3-(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]- -amide, Propane-1-sulfonic acid [2,4-difluoro-3-(5-pyridin-4-yl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phe- nyl]-amide, Propane-1-sulfonic acid {2,4-difluoro-3-[5-(6-methoxy-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-c- arbonyl]-phenyl}-amide, Propane-1-sulfonic acid {2,4-difluoro-3-[5-(6-morpholin-4-yl-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyrid- ine-3-carbonyl]-phenyl}-amide, Propane-1-sulfonic acid (2,4-difluoro-3-{5-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-1H-pyrrolo[- 2,3-b]pyridine-3-carbonyl}-phenyl)-amide, Propane-1-sulfonic acid {2,4-difluoro-3-[5-(4-methyl-1H-imidazol-2-yl)-1H-pyrrolo[2,3-b]pyridine-- 3-carbonyl]-phenyl}-amide, Propane-1-sulfonic acid {2,4-difluoro-3-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3- -carbonyl]-phenyl}-amide, and pharmaceutically acceptable salts thereof.

21. The compound of claim 1, wherein the compound is selected from the group consisting of: Propane-1-sulfonic acid [2,4-difluoro-3-(5-phenylamino-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phen- yl]-amide, Propane-1-sulfonic acid {2,4-difluoro-3-[5-(4-methyl-piperidin-1-yl)-1H-pyrrolo[2,3-b]pyridine-3-- carbonyl]-phenyl}-amide, Propane-1-sulfonic acid {2,4-difluoro-3-[5-(4-methyl-piperazin-1-yl)-1H-pyrrolo[2,3-b]pyridine-3-- carbonyl]-phenyl}-amide, and pharmaceutically acceptable salts thereof.

22. The compound of claim 1, wherein the compound is selected from the group consisting of: Dimethylamine-1-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, Dimethylamine-1-sulfonic acid [3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide, Dimethylamine-1-sulfonic acid [3-(5-phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, Piperidine-1-sulfonic acid [2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide, Piperidine-1-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, Dimethylamine-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluor- o-phenyl}-amide, and pharmaceutically acceptable salts thereof.

23. The compound of claim 1, wherein the compound is selected from the group consisting of: N-{3-[5-(4-Chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-diflu- oro-phenyl}-4-trifluoromethyl-benzenesulfonamide, N-[3-(5-Ethyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-- 4-trifluoromethyl-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -3-fluoro-4-methyl-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -4-methyl-benzenesulfonamide, N-(2,4-Difluoro-3-{5-[4-(2-methoxy-ethoxy)-phenyl]-1H-pyrrolo[2,3-b]pyrid- ine-3-carbonyl}-phenyl)-4-trifluoromethyl-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- benzenesulfonamide, N-[2,4-Difluoro-3-(5-fluoro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]- -benzenesulfonamide, N-{2,4-difluoro-3-[5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-b]pyridine-3-carbo- nyl]-phenyl}-4-trifluoromethyl-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -2-methyl-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -5-fluoro-2-methyl-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -3-methyl-benzenesulfonamide, N-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-2-methyl- -benzenesulfonamide, N-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-3-methyl- -benzenesulfonamide, N-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-4-isopro- pyl-benzenesulfonamide, N-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-benzenes- ulfonamide, N-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-5-fluoro- -2-methyl-benzenesulfonamide, N-[2,4-Difluoro-3-(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-p- henyl]-benzenesulfonamide, N-{2,4-Difluoro-3-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine- -3-carbonyl]-phenyl}-4-trifluoromethyl-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]benz- enesulfonamide, N-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-4-triflu- oromethyl-benzenesulfonamide, and pharmaceutically acceptable salts thereof.

24. The compound of claim 1, wherein the compound is selected from the group consisting of: N-[2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)phenyl]-3-methoxy- -benzenesulfonamide, N-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-4-methox- y-benzenesulfonamide, 4-Butoxy-N-[2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]- -benzenesulfonamide, N-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-3,4-dime- thoxy-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -4-methoxy-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -3-methoxy-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -2,4-dimethoxy-benzenesulfonamide, 2,3-Dihydro-benzo[1,4]dioxine-6-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-ph- enyl]-2,5-dimethoxy-benzenesulfonamide, N-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-2,4-dime- thoxy-benzenesulfonamide, 2,3-Dihydro-benzo[1,4]dioxine-6-sulfonic acid [2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -4-difluoromethoxy-benzenesulfonamide, and pharmaceutically acceptable salts thereof.

25. The compound of claim 1, wherein the compound is selected from the group consisting of: 4-Chloro-N-[2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]- -benzenesulfonamide, 3,4-Dichloro-N-[2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phe- nyl]-benzenesulfonamide, N-[2,4-Difluoro-3-(5-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl- ]-3-fluoro-benzenesulfonamide, N-[2,4-Difluoro-3-(5-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl- ]-4-fluoro-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -3-fluoro-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -4-fluoro-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -3,5-difluoro-benzenesulfonamide, N-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-4-fluoro- -benzenesulfonamide, N-{2,4-Difluoro-3-[5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-b]pyridine-3-carbo- nyl]-phenyl}-4-fluoro-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -2-fluoro-benzenesulfonamide, and pharmaceutically acceptable salts thereof.

26. The compound of claim 1, wherein the compound is selected from the group consisting of: N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -4-cyano-benzenesulfonamide, N-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -4-oxazol-5-yl-benzenesulfonamide, N-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-4-oxazol- -5-yl-benzenesulfonamide, N-{4-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phen- ylsulfamoyl]-phenyl}-acetamide, N-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-3-nitro-- benzenesulfonamide, N-{4-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenylsulfamo- yl]-phenyl}-acetamide, 2-Cyano-N-[2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-- benzenesulfonamide, 3-Cyano-N-[2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-- benzenesulfonamide, and pharmaceutically acceptable salts thereof.

27. The compound of claim 1, wherein the compound is selected from the group consisting of: Thiophene-3-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, Benzo[b]thiophene-2-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, 5-Pyridin-2-yl-thiophene-2-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, Thiophene-2-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, 2,5-Dimethyl-thiophene-3-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, 5-Isoxazol-5-yl-thiophene-2-sulfonic acid [2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide, 2,5-Dimethyl-thiophene-3-sulfonic acid [2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide, 2,4-Dimethyl-thiazole-5-sulfonic acid [2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide, Benzothiazole-6-sulfonic acid [2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide, 2,4-Dimethyl-thiazole-5-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, 5-Oxazol-5-yl-thiophene-2-sulfonic acid [2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide, 1,2-Dimethyl-1H-imidazole-4-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, 5-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-ph- enylsulfamoyl]-furan-2-carboxylic acid methyl ester, 5-[3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyls- ulfamoyl]-2-methyl-furan-3-carboxylic acid methyl ester, 2,5-Dimethyl-furan-3-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide, 5-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenylsulfa- moyl]-furan-2-carboxylic acid methyl ester, 5-[2,4-Difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenylsulfamoyl]- -2-methyl-furan-3-carboxylic acid methyl ester, 2,5-Dimethyl-furan-3-sulfonic acid [2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide, and pharmaceutically acceptable salts thereof.

28. The compound of claim 1 that is N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -2,4-difluoro-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

29. The compound of claim 1 that is N-[2,4-difluoro-3-(5-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl- ]-3-trifluoromethyl-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

30. The compound of claim 1 that is N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -3-trifluoromethyl-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

31. The compound of claim 1 that is N-[2,4-difluoro-3-(5-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl- ]-4-trifluoromethyl-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

32. The compound of claim 1 that is N-{2,4-difluoro-3-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine- -3-carbonyl]-phenyl}-3-fluoro-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

33. The compound of claim 1 that is N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -2-cyano-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

34. The compound of claim 1 that is N-{2,4-difluoro-3-[5-(6-methoxy-pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3- -carbonyl]-phenyl}-3-fluoro-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

35. The compound of claim 1 that is N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -4-trifluoromethyl-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

36. The compound of claim 1 that is N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -3-cyano-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

37. The compound of claim 1 that is N-{2,4-difluoro-3-[5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-b]pyridine-3-carbo- nyl]-phenyl}-3-fluoro-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

38. The compound of claim 1 that is N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -4-isopropyl-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

39. The compound of claim 1 that is N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]- -4-ethyl-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

40. The compound of claim 1 that is N-[2,4-difluoro-3-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-2,5-dime- thoxy-benzenesulfonamide and any pharmaceutically acceptable salts thereof.

41. The compound of claim 1 that is dimethylamine-1-sulfonic acid [3-(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phe- nyl]-amide and any pharmaceutically acceptable salts thereof.

42. The compound of claim 1 that is butane-1-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-amide and any pharmaceutically acceptable salts thereof.

43. The compound of claim 1 that is N-[2,4-difluoro-3-(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-p- henyl]-ethanesulfonamide and any pharmaceutically acceptable salts thereof.

44. The compound of claim 1 that is propane-1-sulfonic acid [2,4-difluoro-3-(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phe- nyl]-amide and any pharmaceutically acceptable salts thereof.

45. The compound of claim 1 that is propane-1-sulfonic acid [2,4-difluoro-3-(5-morpholin-4-yl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-p- henyl]-amide and any pharmaceutically acceptable salts thereof.

46. The compound of claim 1 that is propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluor- o-phenyl}-amide and any pharmaceutically acceptable salts thereof.

47. The compound of claim 16 that is propane-1-sulfonic acid {2,4-difluoro-3-[5-(4-trifluoromethyl-phenyl)-1H-pyrrolo[2,3-b]pyridine-3- -carbonyl]-phenyl}-amide and any pharmaceutically acceptable salts thereof.

48. The compound of claim 1 that is propane-1-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-a- mide and any pharmaceutically acceptable salts thereof.

49. The compound of claim 1 that is propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2-fluoro-ph- enyl}-amide and any pharmaceutically acceptable salts thereof.

50. The compound of claim 1 that is propane-1-sulfonic acid [3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-amide and any pharmaceutically acceptable salts thereof.

51. The compound of claim 1 that is propane-1-sulfonic acid [4-chloro-2-fluoro-3-(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl- )-phenyl]-amide and any pharmaceutically acceptable salts thereof.

52. The compound of claim 1 that is propane-1-sulfonic acid [2-fluoro-3-(5-fluoro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide and any pharmaceutically acceptable salts thereof.

53. The compound of claim 16 that is propane-1-sulfonic acid {2,4-difluoro-3-[5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-b]pyridine-3-carbony- l]-phenyl}-amide and any pharmaceutically acceptable salts thereof.

54. The compound of claim 1, wherein the compound is selected from the group consisting of: Propane-1-sulfonic acid [3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-am- ide, N-[3-(5-Bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phen- yl]-benzenesulfonamide, Propane-1-sulfonic acid [3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-4-chloro-2-fluoro-pheny- l]-amide, Dimethylamine-1-sulfonic acid [3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-am- ide, Propane-1-sulfonic acid [3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-amide, Butane-1-sulfonic acid [3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-am- ide, Thiophene-3-sulfonic acid [3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-am- ide, and pharmaceutically acceptable salts thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc